Recital 35, Regulation (EU) 2026/1826

In forcesince 28 Jul 2026

Two applications for the renewal of the approval of the active substance penconazole were submitted on 21 and 29 December 2016, respectively, and the rapporteur Member State informed the co-rapporteur Member State, the Commission and the Authority on 17 January 2017 that it had assessed the admissibility of the applications pursuant to Article 3 of Implementing Regulation (EU) No 844/2012, and in particular their completeness and timeliness, and concluded that they were admissible. The applications have been made public by the Authority. On 19 November 2021, the rapporteur Member State submitted the draft renewal assessment report to the Authority, which conducted a public consultation on it between 22 August and 21 October 2022. On 9 February 2023, the Authority requested additional information for the purposes of the renewal assessment pursuant to Article 13(3) of Implementing Regulation (EU) No 844/2012 and the applicants submitted that information on 6 and 13 March 2023, respectively, within the deadline given. On 28 July 2025, the Authority requested additional information for the purposes of assessment of the approval criteria concerning endocrine disrupting properties set out in points 3.6.5 and 3.8.2 of Annex II to Regulation (EC) No 1107/2009, as amended by Regulation (EU) 2018/605, pursuant to Article 13(3a) of Implementing Regulation (EU) No 844/2012 to be submitted by the applicants by 27 March 2027 and the submission is pending. As the Authority estimates that it will need 120 days after receiving the revised draft renewal assessment report to complete the evaluation and to finalise its conclusion for penconazole, and as the Commission will need time to adopt the ensuing risk management decisions, the duration of the extension of the approval period should be set at 28 months, until 15 February 2029.